Edgewise Therapeutics(EWTX)

Focus: Edgewise is a public-stage biotechnology company focused on small-molecule therapeutics for musculoskeletal diseases, particularly muscular dystrophies. The company operates as a lean, early-stage biotech with a focused pipeline and minimal commercial infrastructure to date.

Musculoskeletal

Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Edgewise Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Edgewise Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

18 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Defining Endpoints in Becker Muscular Dystrophy

Becker Muscular Dystrophy

N/A

Clinical Trials (1)

NCT05257473Defining Endpoints in Becker Muscular Dystrophy

N/A

Help build intelligence for Edgewise Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead development of first-in-class small molecules for rare, high-unmet-need muscular dystrophies with significant commercial upside
Opportunity to shape commercial strategy from ground zero with 5 commercial hires already building infrastructure
Public company status provides equity liquidity and access to capital markets, reducing typical startup failure risk

Watch Out For

Severely constrained cash position ($42M in FY 2025, down from $86M YoY) with $100M+ annual net losses and no revenue—runway uncertain without capital raise
No Phase 3 programs and only 1 Phase 2 candidate (Sevasemten) with meaningful clinical traction; pipeline is heavily early-stage with 11 Phase 1 studies

Generated by Claude from Edgewise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

Becker Muscular Dystrophy

N/A

Clinical Trials (1)

NCT04349566Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

N/A

EDG-7500

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT06011317A Study of EDG-7500 in Healthy Adults

Phase 1